How to Value a Laboratory Services Business in 2026

Laboratory services is one of the most active M&A sectors I work in, and for good reason. The combination of recurring test volume, high barriers to entry (certifications, equipment, trained personnel), and fragmented ownership creates exactly the conditions that private equity loves. But "laboratory services" is actually three or four distinct markets that value very differently. Let me walk through each one and explain what drives multiples in this space.

Laboratory Services Valuation Multiples: The Data

We track 317 laboratory services transactions in our database. The medians are striking: 12.7x EV/EBITDA and 2.29x EV/Revenue. These are well above the broader market because lab businesses combine recurring revenue, technical moats, and consolidation tailwinds.

Even at the smaller end, multiples hold up. Businesses under $5M enterprise value trade at 11.63x EBITDA and 1.04x revenue. The $5-25M bracket trades at 8.46x EBITDA and 1.66x revenue. The apparent compression in EBITDA multiples at the mid-market reflects the mix of lab types at that size — more environmental and materials testing labs, which trade at lower multiples than clinical labs.

The overarching trend is consolidation. Every major lab sub-sector has active platform buyers. If you own a lab business, you're operating in a seller's market — but only if you understand what buyers are paying for.

Clinical Laboratories: The Quest/LabCorp Consolidation Wave

Clinical labs — the labs that process blood work, urinalysis, pathology, genetic testing, and other diagnostic specimens — are the highest-valued segment. The consolidation story here is well-known: Quest Diagnostics and LabCorp have been acquiring for decades, and PE-backed platforms like Eurofins, Sonic Healthcare, and regional players continue to fill in the gaps.

What makes clinical labs valuable is the combination of recurring test volume (patients need lab work repeatedly), high switching costs (physician ordering patterns are sticky), and regulatory barriers (CLIA certification, state licensure, CAP accreditation). A clinical lab with established physician referral networks generates revenue that is about as close to recurring as healthcare gets.

The challenge is reimbursement pressure. PAMA (Protecting Access to Medicare Act) has been cutting clinical lab fee schedules, and commercial payers use Medicare rates as a benchmark. A lab that hasn't diversified beyond routine chemistry and hematology panels is watching its revenue per test decline year over year.

The labs that command top multiples have invested in specialized testing — molecular diagnostics, pharmacogenomics, toxicology panels, infectious disease PCR. These tests reimburse at higher rates, face less pricing pressure, and serve growing end markets. I've seen specialized clinical labs trade at 14-18x EBITDA when they have a defensible niche and growing test volumes.

Environmental Testing Labs: The PFAS Boom

Environmental testing is in the middle of a historic growth cycle, driven primarily by PFAS ("forever chemicals") testing requirements, expanded water quality regulations, and increased environmental remediation activity. If you own an environmental lab with PFAS testing capabilities, you're sitting on a highly valuable asset.

The numbers tell the story. Environmental labs with PFAS, per- and polyfluoroalkyl substances testing capabilities are seeing 20-40% annual revenue growth as EPA regulations expand testing requirements to drinking water systems, contaminated sites, and industrial dischargers. Labs that invested early in the LC-MS/MS equipment and method development for EPA 533 and 1633 are now capacity-constrained — which is exactly the market dynamic that drives premium valuations.

Environmental labs typically trade at 8-12x EBITDA, with PFAS-capable labs at the high end. The key value drivers:

• State certifications: Every state has its own lab certification program. A lab certified in 15-20 states can serve a national customer base. Building that certification portfolio takes years.
• Method scope: The breadth of EPA methods your lab is certified to perform determines your addressable market. Labs with comprehensive air, water, soil, and waste testing capabilities are more attractive than single-matrix specialists.
• PFAS capability and capacity: This is the current gold standard. If you have LC-MS/MS instruments and validated PFAS methods, your lab is worth meaningfully more than it was three years ago.
• Client diversification: Labs serving a mix of engineering firms, municipalities, industrial clients, and government agencies are less risky than those dependent on a single client segment.

Materials Testing and NDT Labs: Infrastructure Tailwinds

Materials testing labs — concrete testing, soil testing, asphalt testing, non-destructive testing (NDT), welding inspection — serve the construction and infrastructure markets. The Infrastructure Investment and Jobs Act has been a significant tailwind, driving increased testing volume across transportation, water, and energy infrastructure projects.

These labs typically trade at 6-9x EBITDA, lower than clinical or environmental labs because the work is more project-based and margins are thinner. However, labs with recurring inspection contracts — annual bridge inspections, ongoing construction quality assurance programs, long-term monitoring agreements — command premium multiples because they've converted project work into predictable revenue.

NDT specialists (ultrasonic, radiographic, magnetic particle, liquid penetrant testing) are particularly attractive to buyers when they serve the energy sector — pipeline inspection, refinery turnaround testing, wind turbine inspection. The combination of safety-critical work, certified technician requirements, and recurring inspection schedules creates a sticky revenue base.

Certifications: The Moat That Matters Most

In every lab sub-sector, certifications are the primary barrier to entry and the most important value driver. I've seen labs where the certification portfolio is worth more than the equipment.

Clinical labs: CLIA certification is mandatory. CAP (College of American Pathologists) accreditation is the gold standard and opens doors to reference lab contracts. State-specific licenses (New York, California, Pennsylvania, Florida are the most restrictive) create geographic moats.

Environmental labs: NELAP/TNI accreditation plus individual state certifications. Some states (New Jersey, New York) have particularly rigorous programs that take 12-18 months to obtain.

Materials testing labs: AASHTO accreditation, ASTM method certifications, NQA-1 for nuclear work, NADCAP for aerospace. Each certification opens a specific market segment and takes time to achieve.

The strategic implication for sellers: every certification you hold is a barrier that a new entrant would need years to replicate. Document your certification portfolio comprehensively and present it as a competitive moat during the sale process.

What Drives Premium Multiples in Lab Businesses

Across all lab types, I see the same factors separating premium exits from average ones:

Test menu breadth. A lab that can handle a wide range of tests keeps clients from splitting work across multiple providers. This creates stickiness and cross-selling opportunities. Buyers look at revenue per client and see upside when the test menu supports expansion.

Equipment vintage. Lab equipment has limited useful life, and replacement costs are substantial. A lab with modern instruments (LC-MS, ICP-MS, GC-MS/MS, automated sample prep) that have 5-7 years of useful life remaining is worth more than one where the equipment fleet needs imminent replacement. I always recommend sellers prepare a detailed equipment list with acquisition dates and estimated remaining life.

Specimen/sample volume trends. Buyers want to see consistent or growing volume. Declining test volumes signal market share loss or end-market weakness. Three years of stable or growing volume data is powerful evidence for a premium multiple.

Turnaround time performance. Labs that consistently meet or beat their published turnaround times earn customer loyalty and can charge premium prices. Buyers look at TAT metrics as a proxy for operational excellence.

The Staffing Challenge

I'd be remiss not to mention the elephant in the room: lab staffing. The shortage of medical technologists, chemists, and certified technicians is real and getting worse. Labs that have solved the staffing problem — through competitive compensation, training programs, partnerships with universities, or automation that reduces headcount requirements — are significantly more attractive to buyers.

I've seen deals where the buyer discounted the price by 15-20% because the lab was running with 3-4 unfilled positions and relying on overtime and temporary staff to maintain output. That's not a sustainable operating model, and buyers price the risk accordingly.

How to Maximize Your Lab Business Value

Expand your certification portfolio.Every new state certification or method accreditation you add expands your addressable market. If you're an environmental lab certified in 10 states, getting to 20 meaningfully increases your value to a national platform buyer.

Invest in high-value testing capabilities. For clinical labs, that means molecular and genetic testing. For environmental labs, PFAS and emerging contaminants. For materials labs, advanced NDT methods. These investments pay for themselves in margin improvement and exit multiple enhancement.

Build recurring revenue. Convert project-based clients to annual contracts wherever possible. Monitoring agreements, routine compliance testing schedules, and subscription pricing models all increase the predictability of your revenue — and buyers pay a premium for predictability.

Document everything. SOPs, method validations, quality manuals, training records, equipment maintenance logs. Buyers in lab services conduct thorough operational due diligence. The better your documentation, the faster and smoother the deal process.

The Bottom Line

Laboratory services businesses are benefiting from strong consolidation dynamics, regulatory tailwinds, and the fundamental fact that testing demand tends to grow over time as regulations expand and quality requirements increase. Whether you operate a clinical reference lab, an environmental testing facility, or an NDT inspection firm, the key to maximizing your exit is the same: invest in certifications, diversify your client base, build recurring revenue, and maintain modern equipment. The market is rewarding well-run labs with premium multiples — make sure yours is positioned to capture that premium.